文献速递泌尿生殖介入MRUS

磁共振引导聚焦超声局灶治疗前列腺癌:Ⅰ期试验两年随访的并发症与功能结局

Focal Therapy for Prostate Cancer with In-Bore MR-guided Focused Ultrasound: Two-Year Follow-up of a Phase I Trial-Complications and Functional Outcomes.
PubMed 文献 · Radiology · 2017-06-26

这项前瞻性单臂Ⅰ期试验纳入14例未治疗的低体积低级别前列腺癌患者,行MR引导聚焦超声局灶消融,12例完成2年随访。7例出现Clavien-Dindo 1-2级并发症,EPIC各子域评分24个月内较基线无显著变化;6个月模板活检1例、24个月3例Gleason评分大于6。作者认为该技术可行且早期安全性和功能结局似乎良好,但需进一步临床试验确立肿瘤学疗效。

要点

  • MR引导聚焦超声局灶消融前列腺癌在技术上可行,早期安全性和功能结局似乎良好。
  • 14例中7例出现Clavien-Dindo 1-2级并发症;EPIC各子域评分24个月内较基线无显著变化。
  • 6个月模板活检1例、24个月3例Gleason评分大于6;肿瘤学疗效尚需进一步临床试验确立。

核心结论

  • MR引导聚焦超声用于前列腺局灶消融在技术上可行,似乎具有良好的早期安全性和功能结局;仍需进一步临床试验确立肿瘤学疗效。

研究设计与样本

  • 前瞻性单臂Ⅰ期试验,经集中机构审查委员会伦理批准并获患者知情同意;2011年7月至2013年2月纳入14例未治疗的低体积低级别前列腺癌患者(临床分期T2a或更低、Gleason评分3+3、索引肿瘤≤10 mm3),12例完成2年随访;所有患者行机器人经会阴模板穿刺活检和多参数MR成像,仅纳入模板活检最多两个病灶且小于10 mm者;靶区在实时MR测温监控下超声消融,并将关键区域排除在声束路径之外。

诊断标准与关键数值

  • 纳入标准为未治疗的低体积低级别前列腺癌:临床分期T2a或更低、Gleason评分3+3、索引肿瘤≤10 mm3,且模板活检最多两个病灶、病灶小于10 mm。

临床应用与阅片要点

  • 作者认为MR引导聚焦超声用于前列腺局灶消融在技术上可行,似乎具有有利的早期安全性和功能结局;作者指出仍需进一步临床试验以确立肿瘤学疗效。

局限性

  • 原文结论指出仍需进一步临床试验以确立肿瘤学疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To report the safety profile and 2-year functional outcomes of in-bore magnetic resonance (MR)-guided focused ultrasound on single cancer foci in men with prostate cancer. Materials and Methods Ethics approval was obtained from the centralized institutional review board for this prospective single-arm study, and patients provided informed consent. Patients with untreated low-volume low-grade prostate cancer (clinical stage T2a or lower; Gleason score, 3+3; index tumor ≤10 mm3) underwent MR-guided focused ultrasound between July 2011 and February 2013. All patients underwent robotic transperineal mapping biopsy and multiparametric MR imaging. Only those with a maximum of two lesions smaller than 10 mm at mapping biopsy were included. Target areas were sonicated with real-time MR thermometry monitoring, excluding critical areas from the beam path. Serum prostate-specific antigen (PSA) and Expanded Prostate Index Composite (EPIC) scores were obtained at baseline and at 1, 3, 6, 12, 18, and 24 months and were plotted to observe their trend. Mean EPIC subdomain score changes at each serial time point were compared with the baseline score by using paired t tests (level of significance, P < .007). Repeat transperineal biopsy was performed at 6 and 24 months. Results Fourteen men (mean age, 62.8 years; median PSA level, 8.3 ng/mL) underwent treatment, with 12 men completing 2-year follow-up. A median reduction of PSA level by 2.9 ng/mL was observed at 6 months. Seven men had Clavien-Dindo grade 1-2 complications. There was a slight insignificant deterioration of EPIC urinary symptom score (mean increase of 7.8 points compared with baseline, P = .012) noted at 1 month, but it returned to baseline by 3 months. There was a trend to deterioration in sexual function score (mean decrease, 4.4 points; P = .04 [not significant]) that normalized at 3 months. There was no significant change in EPIC subdomain scores from baseline over the 24 months. At 6-month template biopsy, one man had cancer with a Gleason score greater than 6; at 24 months, three men had cancer with a Gleason score greater than 6. Conclusion MR-guided focused ultrasound is technically feasible for focal prostate ablation and appears to have a favorable early safety and functional profile. Further clinical trials are necessary to establish oncologic efficacy. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Tay KJ, Cheng CWS, Lau WKO, et al. Focal Therapy for Prostate Cancer with In-Bore MR-guided Focused Ultrasound: Two-Year Follow-up of a Phase I Trial-Complications and Functional Outcomes. Radiology. 2017. PMID: 28654336. doi:10.1148/radiol.2017161650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。